UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Nivolumab in patients with advanced renal cell carcinoma in France: interim results of the observational, real-world WITNESS study

ESMO open, 2024-07, Vol.9 (7), p.103602, Article 103602

2024

Volltextzugriff (PDF)

Elderly patients (pts) with advanced Renal Cell Carcinoma (aRCC) treated with Nivolumab (N): A subgroup analysis from the WITNESS real-world study in France

European urology open science (Online), 2020-11, Vol.21, p.S182

2020

Volltextzugriff (PDF)

1805P Efficacy of olaparib (ola) + abiraterone (abi) vs placebo (pbo) + abi in the non-BRCA mutation (non-BRCAm) subgroup of patients (pts) with metastatic castration-resistant prostate cancer (mCPRC) in the PROpel trial

Annals of oncology, 2023-10, Vol.34, p.S975-S976

2023

Volltextzugriff (PDF)

674P WITNESS: Real-world outcomes of patients (pts) with advanced renal cell carcinoma (aRCC) treated with nivolumab in France and subgroup analysis of patients receiving concomitant medications at baseline

Annals of oncology, 2021-09, Vol.32, p.S697-S697

2021

Volltextzugriff (PDF)

PROpel: Efficacy of abiraterone + olaparib vs. abiraterone + placebo in the first-line treatment of patients with asymptomatic/mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) at baseline

European urology, 2023-02, Vol.83, p.S1674-S1675

2023

Volltextzugriff (PDF)

A1160 - PROpel: Efficacy of abiraterone + olaparib vs. abiraterone + placebo in the first-line treatment of patients with asymptomatic/mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) at baseline

European urology, 2023-02, Vol.83, p.S1674-S1675

2023

Volltextzugriff (PDF)

A0841 - Delayed nephrectomy after immunotherapy for metastatic renal cell carcinoma: Oncological outcomes and predictive factors of surgical difficulties

European urology, 2024-03, Vol.85, p.S1864-S1865

2024

Volltextzugriff (PDF)

Delayed nephrectomy after immunotherapy for metastatic renal cell carcinoma: Oncological outcomes and predictive factors of surgical difficulties

European urology, 2024-03, Vol.85, p.S1864-S1865

2024

Volltextzugriff (PDF)

673P Cabozantinib-nivolumab (CN) vs. nivolumab-cabozantinib (NC) in patients (pts) with metastatic clear cell renal cell carcinoma (mRCC) following one prior VEGFR tyrosine kinase inhibitor (TKI): The CABIR multicentric matching-adjusted study

Annals of oncology, 2021-09, Vol.32, p.S696-S697

2021

Volltextzugriff (PDF)

Néphrectomies « de clôture » post-immunothérapie: facteurs prédictifs de complications peropératoires

Progrès en urologie. Formation médicale continue, 2023-11, Vol.33 (3), p.S64

2023

Volltextzugriff (PDF)

Impact of nephrectomy on clinical outcomes and feasibility of radiation therapy in patients (pts) with advanced Renal Cell Carcinoma (aRCC) treated with nivolumab: Subgroup analyses from the WITNESS real-world study in France

European urology open science (Online), 2021-11, Vol.33, p.S321

2021

Volltextzugriff (PDF)

Impact of learning curve and technical changes on dosimetry in low-dose brachytherapy for prostate cancer

Strahlentherapie und Onkologie, 2012-12, Vol.188 (12), p.1091-1095

2012

Volltextzugriff (PDF)

1762P MERINOS: Metastatic non muscle invasive urothelial carcinoma - An observational study

Annals of oncology, 2022-09, Vol.33, p.S1344

2022

Volltextzugriff (PDF)

157O Biomarker analysis and updated results from the phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Annals of oncology, 2022-11, Vol.33, p.S1495-S1495

2022

Volltextzugriff (PDF)

1357O Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Annals of oncology, 2022-09, Vol.33, p.S1160

2022

Volltextzugriff (PDF)

720P Randomised phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen in anti-angiogenic naïve patients with metastatic renal cell carcinoma (mRCC): Interim analysis (IA) of SURF study

Annals of oncology, 2020-09, Vol.31, p.S565-S566

2020

Volltextzugriff (PDF)

Spécificités cliniques des tumeurs de vessie n’infiltrant pas le muscle métastatique d’emblée : étude observationnelle multicentrique merinos

Progrès en urologie. Formation médicale continue, 2022-11, Vol.32 (3), p.S78-S79

2022

Volltextzugriff (PDF)

Résultats oncologiques de la néphrectomie différée après réponse complète à l’immunothérapie pour cancer du rein métastatique au diagnostic

Progrès en urologie (Paris), 2021-11, Vol.31 (13), p.839-840

2021

Volltextzugriff (PDF)

"Last-Mile" preparation for a potential disaster – Interdisciplinary approach towards tsunami early warning and an evacuation information system for the coastal city of Padang, Indonesia

Natural hazards and earth system sciences, 2009-08, Vol.9 (4), p.1509-1528

2009

Volltextzugriff (PDF)

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

Annals of oncology, 2024-01, Vol.35 (1), p.107-117

2024

Volltextzugriff (PDF)

Directional Infragravity Waves Induced by Bichromatic and Bidirectional Waves: Theoretical Approach and Experimental Affirmation

Journal of waterway, port, coastal, and ocean engineering, 2022-09, Vol.148 (5)

2022

Volltextzugriff (PDF)

Risk reduction at the “Last-Mile”: an attempt to turn science into action by the example of Padang, Indonesia

Natural hazards (Dordrecht), 2013, Vol.65 (1), p.915-945

2013

Volltextzugriff (PDF)

Precise determination of sediment dynamics using low-cost GPS-floaters

Proceedings of the 2012 IEEE/ION Position, Location and Navigation Symposium, 2012, p.791-798

2012

Volltextzugriff (PDF)

ORBITAL VELOCITIES DUE TO BICHROMATIC-BIDIRECTIONAL WAVES

Proceedings of Conference on Coastal Engineering, 2023-09 (37), p.59

2023

Volltextzugriff (PDF)

FINDING BICHROMATIC-BIDIRECTIONAL WAVES WITH ADVs

Proceedings of Conference on Coastal Engineering, 2018-12 (36), p.33

2018

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(24)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Nivolumab in patients with advanced renal cell carcinoma in France: interim results of the observational, real-world WITNESS study

Elderly patients (pts) with advanced Renal Cell Carcinoma (aRCC) treated with Nivolumab (N): A subgroup analysis from the WITNESS real-world study in France

1805P Efficacy of olaparib (ola) + abiraterone (abi) vs placebo (pbo) + abi in the non-BRCA mutation (non-BRCAm) subgroup of patients (pts) with metastatic castration-resistant prostate cancer (mCPRC) in the PROpel trial

674P WITNESS: Real-world outcomes of patients (pts) with advanced renal cell carcinoma (aRCC) treated with nivolumab in France and subgroup analysis of patients receiving concomitant medications at baseline

PROpel: Efficacy of abiraterone + olaparib vs. abiraterone + placebo in the first-line treatment of patients with asymptomatic/mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) at baseline

A1160 - PROpel: Efficacy of abiraterone + olaparib vs. abiraterone + placebo in the first-line treatment of patients with asymptomatic/mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) at baseline

A0841 - Delayed nephrectomy after immunotherapy for metastatic renal cell carcinoma: Oncological outcomes and predictive factors of surgical difficulties

Delayed nephrectomy after immunotherapy for metastatic renal cell carcinoma: Oncological outcomes and predictive factors of surgical difficulties

673P Cabozantinib-nivolumab (CN) vs. nivolumab-cabozantinib (NC) in patients (pts) with metastatic clear cell renal cell carcinoma (mRCC) following one prior VEGFR tyrosine kinase inhibitor (TKI): The CABIR multicentric matching-adjusted study

Néphrectomies « de clôture » post-immunothérapie: facteurs prédictifs de complications peropératoires

Impact of nephrectomy on clinical outcomes and feasibility of radiation therapy in patients (pts) with advanced Renal Cell Carcinoma (aRCC) treated with nivolumab: Subgroup analyses from the WITNESS real-world study in France

Impact of learning curve and technical changes on dosimetry in low-dose brachytherapy for prostate cancer

1762P MERINOS: Metastatic non muscle invasive urothelial carcinoma - An observational study

157O Biomarker analysis and updated results from the phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

1357O Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

720P Randomised phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen in anti-angiogenic naïve patients with metastatic renal cell carcinoma (mRCC): Interim analysis (IA) of SURF study

Spécificités cliniques des tumeurs de vessie n’infiltrant pas le muscle métastatique d’emblée : étude observationnelle multicentrique merinos

Résultats oncologiques de la néphrectomie différée après réponse complète à l’immunothérapie pour cancer du rein métastatique au diagnostic

"Last-Mile" preparation for a potential disaster – Interdisciplinary approach towards tsunami early warning and an evacuation information system for the coastal city of Padang, Indonesia

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

Directional Infragravity Waves Induced by Bichromatic and Bidirectional Waves: Theoretical Approach and Experimental Affirmation

Risk reduction at the “Last-Mile”: an attempt to turn science into action by the example of Padang, Indonesia

Precise determination of sediment dynamics using low-cost GPS-floaters

ORBITAL VELOCITIES DUE TO BICHROMATIC-BIDIRECTIONAL WAVES

FINDING BICHROMATIC-BIDIRECTIONAL WAVES WITH ADVs

Suchergebnisse filtern